Marco Meglio

The agent had previously demonstrated positive results in a phase 2a setting, with favorable trends on modified Unified MSA Rating Scale scores across a 12-week period.

The professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed the state of care for Friedrich ataxia and omaveloxolone’s potential to become its first approved therapy.

The submission includes findings from Study 1601, along with long-term safety and efficacy data from Zogenix’s ongoing open-label extension trials.

Despite not achieving statistical significance, there was greater relative reduction in seizure frequency over placebo in those with a structural etiology for focal epilepsy than those without, laying the foundation for future research.

Jessica Caldwell, PhD, director, Women’s Movement Prevention Center, Cleveland Clinic, sat down shed light on the understanding of Alzheimer disease in women and their inclusion in clinical trials.

Between PREVENT baseline and end, mean EDSS and Hauser Ambulation Index scores improved with eculizumab (Soliris; Alexion) monotherapy and deteriorated with placebo alone.

The findings identified Th2-related cytokines as characterizing for the prognosis of acute episodes of NMOSD at 1 month and found serum NfL to be a likely biomarker of disease severity at attack.

The expanded access program is designed to provide individuals with ALS who are not eligible to enroll in the Healey ALS Platform Trial access to CNM-Au8.

More than 80% of those with NMOSD experienced disease relapse 6 months after discontinuation of immunosuppressive therapy.

On World Narcolepsy Day 2021, get a recap of the latest advances in narcolepsy that you might have missed over the last few months, compiled all into one place by the NeurologyLive team.

The director of the Women’s Movement Prevention Center at Cleveland Clinic discussed her new study, and the current knowledge of the role genetics play in Alzheimer disease risk.

Over a 12-month stretch, patients with spinocerebellar ataxia type 2 treated with riluzole showed significant worsening in Composite Cerebellar Functional Severity Score.

Both the 200-mg and 350-mg dose groups showed numerically advantageous differences over placebo in secondary end points such as average daily pain score and 30% reduction in ADP.

Patients previously randomized to omaveloxolone in the core study period continued to show no worsening on modified Friedrich Ataxia Rating Scale relative to their original baseline after nearly 2.5 years of treatment.

Despite not meeting the primary end point, those in the early-start group showed reduced change from baseline in MDS-UPDRS-III scores compared with the delayed-start group at both weeks 52 and 104.

Neurology News Network for the week ending September 18, 2021.

Improvements in mean total amount of time and percentage of participants that were awake suggested limited effect with opicapone (Ogentys; Neurocrine Bio).

Patients with Parkinson disease in both the 24-hour and 16-hour ND0612 dosing regimen groups had ON-state UPDRS-motor scores and UPDRS-ADL scores improve over the 12-month period.

Torticollis was the most common predominant cervical dystonia presentation subtype at injection 1, followed by laterocollis.

When comparing only the lowest and highest HbA1c groups with each other, unadjusted and adjusted regression analysis indicated faster motor progression in the highest group.

The director of IT and Neuroinformatics Development at the Buffalo Neuroimaging provided thoughts on artificial intelligence’s role in neuroimaging and treating multiple sclerosis.

After receiving expanded indication from the FDA as both an acute and preventive treatment of cluster headache, gammaCore becomes the first treatment for paroxysmal hemicrania and hemicrania continua.

The SELECT-HD trial (NCT05032196) is expected to enroll approximately 36 patients with a confirmed diagnosis of early-stage Huntington disease and carry the SNP3 allele in association with their CAG expression.

The use of intravenous thrombolysis prior to mechanical thrombectomy resulted in significantly smaller clots and significantly lower number of fragments than MT therapy alone.

Persons with epilepsy younger than 50 years had a 34-fold increased risk of sudden unexplained death compared with persons without epilepsy.

Current evidence showed little knowledge about the long-term effects of transcranial direct current stimulation in improving patients poststroke.

James E. Galvin, MD, MPH, provided thoughts on the struggles to raise dementia literacy and awareness in underserved, rural, ethnically diverse populations through the ongoing pandemic.

Every patient who underwent physical therapy reported a positive change, ranging from moderately better to much better, while 9 patients on placebo did not notice significant changes or reported worsening of their condition.

Although infusion-related reactions were among the most frequently reported AEs, most patients did not experience them, and the majority of those who did reported mild to moderate reactions.

The assistant professor of neurology at Harvard Medical School provided insight on how to improve care for posttraumatic headache, as well as limitations and benefits to nerve block surgeries.